logo
  

BATM In Strategic Partnership With NEXCOM For Edgility Virtual Networking

BATM Advanced Communications (BVC.L), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announced Friday that its Telco Systems subsidiary has partnered with NEXCOM International Co Ltd, a leading supplier of network appliances, to provide the Group's Edgility virtual networking and edge compute solution pre-installed on NEXCOM's 5G-ready network appliance.

The partnership with NEXCOM, which is headquartered in Taiwan with operations in China, Japan, US, UK and Italy, provides a further route-to-market for the Group's Edgility solution.

By bringing together BATM's software with NEXCOM's hardware, customers can benefit from simpler and streamlined deployment, management and orchestration of networked devices and applications, whilst being cost effective.

Purchasers of the NEXCOM appliance will contract directly with BATM if they choose to use Edgility.

Edgility is available pre-installed on NEXCOM's DTA 1164W uCPE, which provides full support for 5G and IoT connectivity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT